[复发性小细胞肺癌的治疗进展]
[Advances in the Treatment of Relapsed Small Cell Lung Cancer].
作者信息
Liu Bin, Qin Jianwen, Zhou Jingmin
机构信息
Department of Respiratory and Critical Care, Tianjin Chest Hospital, Tianjin 300222, China.
出版信息
Zhongguo Fei Ai Za Zhi. 2017 Mar 20;20(3):192-198. doi: 10.3779/j.issn.1009-3419.2017.03.08.
Abstract
Small cell lung cancer (SCLC) is a highly malignant tumor. The initial treatment of radiotherapy and chemotherapy are more sensitive, high remission rate, but susceptible to drug resistance and relapse after treatment. Although the treatment of lung cancer has undergone enormous changes in recent years, treatment for relapsed SCLC is still a difficult problem in clinical field. In view of the serious resistance of recurrent SCLC to the existing chemotherapeutic drugs, the research on recurrent SCLC around the world is focused on the clinical trial of new drug development, optimization of chemotherapy regimen and target drug development. This paper summarize and estimate studies and literature reports of chemotherapy and precision therapy for relapsed SCLC, hopefully it could help clinicians treat relapsed SCLC and give us clinical research direction for relapsed SCLC in the future.
摘要
小细胞肺癌（SCLC）是一种高度恶性的肿瘤。初始放疗和化疗治疗较为敏感，缓解率高，但治疗后易产生耐药性和复发。尽管近年来肺癌治疗发生了巨大变化，但复发SCLC的治疗仍是临床领域的难题。鉴于复发性SCLC对现有化疗药物严重耐药，世界各地对复发性SCLC的研究集中在新药开发的临床试验、化疗方案优化和靶向药物开发上。本文总结并评估复发性SCLC化疗和精准治疗的研究及文献报道，希望能帮助临床医生治疗复发性SCLC，并为未来复发性SCLC的临床研究提供方向。
相似文献
1
[Advances in the Treatment of Relapsed Small Cell Lung Cancer].[复发性小细胞肺癌的治疗进展]
Zhongguo Fei Ai Za Zhi. 2017 Mar 20;20(3):192-198. doi: 10.3779/j.issn.1009-3419.2017.03.08.
2
[Research progress of anti-angiogenic drugs in the treatment of small cell lung cancer].抗血管生成药物治疗小细胞肺癌的研究进展
Zhonghua Zhong Liu Za Zhi. 2020 Aug 23;42(8):624-628. doi: 10.3760/cma.j.cn112152-20200217-00097.
3
Development of molecularly targeted agents and immunotherapies in small cell lung cancer.小细胞肺癌中分子靶向药物和免疫疗法的发展
Eur J Cancer. 2016 Jun;60:26-39. doi: 10.1016/j.ejca.2016.03.004. Epub 2016 Apr 7.
4
[New Advances in the Treatment for Small Cell Lung Cancer].[小细胞肺癌治疗的新进展]
Zhongguo Fei Ai Za Zhi. 2019 Jun 20;22(6):355-362. doi: 10.3779/j.issn.1009-3419.2019.06.05.
5
Managing Patients With Relapsed Small-Cell Lung Cancer.管理复发性小细胞肺癌患者。
J Oncol Pract. 2018 Jun;14(6):359-366. doi: 10.1200/JOP.18.00204.
6
A retrospective study of amrubicin monotherapy for the treatment of relapsed small cell lung cancer in elderly patients.一项关于氨柔比星单药治疗老年复发性小细胞肺癌的回顾性研究。
Cancer Chemother Pharmacol. 2017 Sep;80(3):615-622. doi: 10.1007/s00280-017-3403-9. Epub 2017 Jul 31.
7
Anti-angiogenesis treatment in a patient with appendix metastasis of small cell lung cancer: A case report.小细胞肺癌阑尾转移患者的抗血管生成治疗：一例报告
Medicine (Baltimore). 2019 Apr;98(16):e15333. doi: 10.1097/MD.0000000000015333.
8
Rechallenge treatment with a platinum-based regimen in patients with sensitive relapsed small-cell lung cancer.在敏感复发性小细胞肺癌患者中用铂类方案进行再挑战治疗。
Med Oncol. 2018 Apr 2;35(5):61. doi: 10.1007/s12032-018-1123-6.
9
Molecular subtyping of small cell lung cancer.小细胞肺癌的分子分型
Semin Cancer Biol. 2022 Nov;86(Pt 2):450-462. doi: 10.1016/j.semcancer.2022.05.010. Epub 2022 May 21.
10
[Molecular targeted therapies in small-cell lung cancer].[小细胞肺癌的分子靶向治疗]
Bull Cancer. 2010 May;97(5):535-45. doi: 10.1684/bdc.2010.1035.
引用本文的文献
1
Apatinib as maintenance therapy following standard first-line chemotherapy in extensive disease small cell lung cancer: A phase II single-arm trial.阿帕替尼作为广泛期小细胞肺癌一线标准化疗后维持治疗的疗效观察：一项Ⅱ期单臂临床试验。
Thorac Cancer. 2022 Feb;13(4):557-562. doi: 10.1111/1759-7714.14298. Epub 2022 Jan 14.
2
A randomized phase 2 trial of apatinib vs observation as maintenance treatment following first-line induction chemotherapy in extensive- stage small cell lung cancer.一项阿帕替尼对比观察用于广泛期小细胞肺癌一线诱导化疗后维持治疗的随机 2 期临床试验。
Invest New Drugs. 2020 Feb;38(1):148-159. doi: 10.1007/s10637-019-00828-x. Epub 2019 Aug 9.
3
Wentilactone A induces cell apoptosis by targeting AKR1C1 gene via the IGF-1R/IRS1/PI3K/AKT/Nrf2/FLIP/Caspase-3 signaling pathway in small cell lung cancer.文替内酯A通过IGF-1R/IRS1/PI3K/AKT/Nrf2/FLIP/半胱天冬酶-3信号通路靶向AKR1C1基因诱导小细胞肺癌细胞凋亡。
Oncol Lett. 2018 Nov;16(5):6445-6457. doi: 10.3892/ol.2018.9486. Epub 2018 Sep 24.
4
[Apatinib as Salvage Therapy for Heavily Pretreated SCLC].阿帕替尼作为经多线治疗的小细胞肺癌的挽救治疗手段
Zhongguo Fei Ai Za Zhi. 2018 Jul 20;21(7):565-570. doi: 10.3779/j.issn.1009-3419.2018.07.11.
本文引用的文献
1
PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer?单独使用PD-1检查点阻断疗法或联合使用PD-1和CTLA-4阻断疗法作为肺癌的免疫疗法？
Expert Opin Biol Ther. 2017 Mar;17(3):305-312. doi: 10.1080/14712598.2017.1280454. Epub 2017 Jan 18.
2
Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study.洛伐匹妥珠单抗替西瑞林，一种靶向DLL3的抗体药物偶联物，用于复发性小细胞肺癌：一项首次人体、同类首创、开放标签的1期研究。
Lancet Oncol. 2017 Jan;18(1):42-51. doi: 10.1016/S1470-2045(16)30565-4. Epub 2016 Dec 5.
3
Design and Synthesis of Tesirine, a Clinical Antibody-Drug Conjugate Pyrrolobenzodiazepine Dimer Payload.临床抗体药物偶联物吡咯并苯二氮䓬二聚体有效载荷替西瑞林的设计与合成。
ACS Med Chem Lett. 2016 May 24;7(11):983-987. doi: 10.1021/acsmedchemlett.6b00062. eCollection 2016 Nov 10.
4
A Partial Response to Reintroduced Chemotherapy in a Resistant Small Cell Lung Cancer Patient After Priming with RRx-001.RRx-001预处理后，一名耐药小细胞肺癌患者对重新引入的化疗产生部分反应。
Clin Med Insights Oncol. 2016 Nov 6;10:105-108. doi: 10.4137/CMO.S40429. eCollection 2016.
5
Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer.三期随机临床试验：伊匹单抗联合依托泊苷和铂类药物与安慰剂联合依托泊苷和铂类药物治疗广泛期小细胞肺癌。
J Clin Oncol. 2016 Nov 1;34(31):3740-3748. doi: 10.1200/JCO.2016.67.6601.
6
PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer.PARP抑制剂活性与SLFN11表达相关，并在小细胞肺癌中与替莫唑胺表现出协同作用。
Clin Cancer Res. 2017 Jan 15;23(2):523-535. doi: 10.1158/1078-0432.CCR-16-1040. Epub 2016 Jul 20.
7
Albumin-bound paclitaxel for the treatment of refractory or relapsed small-cell lung cancer.白蛋白结合型紫杉醇用于治疗难治性或复发性小细胞肺癌。
Mol Clin Oncol. 2016 Jul;5(1):213-215. doi: 10.3892/mco.2016.887. Epub 2016 May 6.
8
Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial.联合顺铂、依托泊苷和伊立替康化疗与拓扑替康单药二线治疗敏感复发性小细胞肺癌患者（JCOG0605）：一项多中心、开放标签、随机 3 期临床试验。
Lancet Oncol. 2016 Aug;17(8):1147-1157. doi: 10.1016/S1470-2045(16)30104-8. Epub 2016 Jun 14.
9
Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial.纳武利尤单抗单药治疗及纳武利尤单抗联合伊匹单抗治疗复发性小细胞肺癌（CheckMate 032）：一项多中心、开放标签、Ⅰ/Ⅱ期试验。
Lancet Oncol. 2016 Jul;17(7):883-895. doi: 10.1016/S1470-2045(16)30098-5. Epub 2016 Jun 4.
10
Genomic Landscape Survey Identifies SRSF1 as a Key Oncodriver in Small Cell Lung Cancer.基因组图谱研究确定SRSF1是小细胞肺癌中的关键致癌驱动因子。
PLoS Genet. 2016 Apr 19;12(4):e1005895. doi: 10.1371/journal.pgen.1005895. eCollection 2016 Apr.
Zotero 插件